Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats

por Netland, I. A., Førde, H. E., Sleire, L., Leiss, L., Rahman, M. A., Skeie, B. S., Miletic, H., Enger, P. Ø., Goplen, D.
Publicado 2016

Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models

por Netland, I. A., Førde, H. E., Sleire, L., Leiss, L., Rahman, M. A., Skeie, B. S., Gjerde, C. H., Enger, P. Ø., Goplen, D.
Publicado 2016

P14.09 BORTEM-17: A Phase IB/II Single-Arm, Control Non-Randomized, Multicentre, Open Label Clinical Trial for Recurrent Glioblastoma with unmethylated MGMT promoter (NCT03643549)

por Goplen, D, Rahman, M A, Arnesen, V S, Brekke, J, Simonsen, A, Andreas, W, Marienhagen, K, Oltedal, L, Haasz, J, Miletic, H, Solheim, T S, Brandal, P, Lie, S A, Chekenya, M
Publicado 2021

Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)

por Eriksson, M., Reichardt, P., Joensuu, H., Krarup-Hansen, A., Hagberg, O., Hohenberger, P., Hagberg, H., Hansson, L., Foukakis, T., Pulkkanen, K., Bauer, S., Goplen, D., Blach Rossen, P., Sundby Hall, K.
Publicado 2021